Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114973) titled 'Mechanistic Exploration and Clinical Impact of Tisotumab Vedotin-Related Adverse Effects: Integrating FAERS Data Mining, Network Pharmacology, Molecular Docking, and Real-World Evidence' on Dec. 19, 2025.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Condition:
Malignant tumor
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-12-20
Target Sample Size: Vitesoltumab observation group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=29463...